NEW YORK, Jan. 30, 2014 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
PharmaPoint: Atopic Dermatitis - Current and Future Players
http://www.reportlinker.com/p01957648/PharmaPoint-Atopic-Dermatitis---Current-and-Future-Players.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology
PharmaPoint: Atopic Dermatitis - Current and Future Players
Summary
GlobalData has released its pharma report, "PharmaPoint: Atopic Dermatitis - Current and Future Players". The report is a vital source of up-to-date information with in-depth analysis on the companies in the rapidly growing Atopic Dermatitis Market. The report identifies and analyses the key companies shaping and driving the global Atopic Dermatitis market. The report provides insight into the competitive Atopic Dermatitis landscape, including new companies entering the market. This report is built using data and information sourced from proprietary databases, primary and secondary and in-house analysis by GlobalData's team of industry experts.
Scope
- Investigation of current and future market competition for Atopic Dermatitis
- Competitor assessment
- Coverage of key market players and company profiles including business description, financial overview and SWOT analysis.
- Strategic assessment of the Atopic Dermatitis sector through market impact analysis, future market scenario and company analysis
Reasons to buy
- Gain a high level view of the trends shaping and driving the Atopic Dermatitis Market
- Assess competitiveness of products in market by understanding the strengths and weaknesses of current competition.
- Create an effective counter-strategy to gain a competitive advantage against those currently in the market
- What's the next big thing in the global Atopic Dermatitis market landscape? Identify, understand and capitalize
1 Table of Contents
1 Table of Contents 7
1.1 List of Tables 9
1.2 List of Figures 9
2 Introduction 10
2.1 Catalyst 10
2.2 Related Reports 10
2.3 Upcoming Related Reports 11
3 Market Outlook 12
3.1 Global Markets 12
3.1.1 Forecast 12
3.1.2 Global Drivers and Barriers 16
4 Current and Future Players 22
4.1 Overview 22
4.2 Trends in Corporate Strategy 24
4.3 Company Profiles 26
4.3.1 Astellas 26
4.3.2 Meda 29
4.3.3 Regeneron 31
4.3.4 Anacor 33
5 Appendix 36
5.1 Bibliography 36
5.2 Abbreviations 37
5.3 Methodology 37
5.4 Forecasting Methodology 37
5.4.1 Diagnosed Atopic Dermatitis Patients 38
5.4.2 Percent Drug-treated Patients 38
5.4.3 Drugs Included in Each Therapeutic Class 39
5.4.4 General Pricing Assumptions 39
5.4.5 Generic Erosion 40
5.5 Physicians and Specialists Included in this Study 41
5.6 Primary Research - Prescriber Survey 42
5.7 About the Authors 43
5.7.1 Author 43
5.7.2 Global Head of Healthcare 44
5.8 About GlobalData 45
5.9 Disclaimer 45
1.1 List of Tables
Table 1: Global Sales Forecasts ($m) for Atopic Dermatitis, 2012-2022 14
Table 2: Global Atopic Dermatitis Market - Drivers and Barriers, 2012-2022 16
Table 3: Key Companies in the Atopic Dermatitis Market, 2013 23
Table 4: Astellas Pharma's Atopic Dermatitis Portfolio Assessment, 2013 28
Table 5: Astellas Pharma SWOT Analysis, 2013 28
Table 6: Meda's Atopic Dermatitis Portfolio Assessment, 2013 30
Table 7: Meda SWOT Analysis, 2013 30
Table 8: Regeneron's Atopic Dermatitis Portfolio Assessment, 2013 32
Table 9: Regeneron SWOT Analysis, 2013 32
Table 10: Anacor's Atopic Dermatitis Portfolio Assessment, 2013 34
Table 11: Anacor's SWOT Analysis, 2013 35
Table 12: Physicians Surveyed, By Country 42
1.2 List of Figures
Figure 1: Global Sales for Atopic Dermatitis by Region, 2012-2022 15
Figure 2: Company Portfolio Gap Analysis in Atopic Dermatitis, 2012-2022 24
To order this report: PharmaPoint: Atopic Dermatitis - Current and Future Players
http://www.reportlinker.com/p01957648/PharmaPoint-Atopic-Dermatitis---Current-and-Future-Players.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology
__________________________
Contact Clare: [email protected]
US: (339)-368-6001
Intl: +1 339-368-6001
SOURCE Reportlinker
Share this article